168 related articles for article (PubMed ID: 15761241)
1. Insulin-like growth factor I and impaired glucose tolerance.
Dunger D; Yuen K; Ong K
Horm Res; 2004; 62 Suppl 1():101-7. PubMed ID: 15761241
[TBL] [Abstract][Full Text] [Related]
2. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
Yuen KC; Dunger DB
Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
[TBL] [Abstract][Full Text] [Related]
3. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes.
Dunger DB; Ong KK; Sandhu MS
Horm Res; 2003; 60 Suppl 3():131-5. PubMed ID: 14671410
[TBL] [Abstract][Full Text] [Related]
5. Chronic alcohol consumption, type 2 diabetes mellitus, insulin-like growth factor-I (IGF-I), and growth hormone (GH) in ethanol-treated diabetic rats.
Kim SJ; Ju A; Lim SG; Kim DJ
Life Sci; 2013 Nov; 93(21):778-82. PubMed ID: 24084046
[TBL] [Abstract][Full Text] [Related]
6. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
Yuen KC; Dunger DB
Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
[TBL] [Abstract][Full Text] [Related]
8. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
9. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
10. [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes].
Kato M
Hokkaido Igaku Zasshi; 1998 Nov; 73(6):613-25. PubMed ID: 10036618
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus.
Bereket A; Lang CH; Wilson TA
Horm Metab Res; 1999; 31(2-3):172-81. PubMed ID: 10226799
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M
J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010
[TBL] [Abstract][Full Text] [Related]
13. Mecasermin (recombinant human insulin-like growth factor I).
Rosenbloom AL
Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
[TBL] [Abstract][Full Text] [Related]
14. Polysomnographic sleep, growth hormone insulin-like growth factor-I axis, leptin, and weight loss.
Rasmussen MH; Wildschiødtz G; Juul A; Hilsted J
Obesity (Silver Spring); 2008 Jul; 16(7):1516-21. PubMed ID: 18464752
[TBL] [Abstract][Full Text] [Related]
15. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
16. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy].
Peczyńska J; Urban M; Głowińska B; Urban B
Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196
[TBL] [Abstract][Full Text] [Related]
17. [Role of the steroids, SHBG, IGF-1, IGF BP-3 and growth hormone in glucose metabolism disorders during long-term treatment with low doses of glucocorticoids].
Vondra K; Hampl R; Nĕmcová D; Hill M; Hoza J; Kot'átková A; Stárka L; Vrbíková J; Zamrazil V
Cas Lek Cesk; 2002 Feb; 141(3):89-95. PubMed ID: 11925670
[TBL] [Abstract][Full Text] [Related]
18. Individual igf-I responsiveness to a fixed regimen of low-dose growth hormone replacement is increased with less variability in obese compared to non-obese adults with severe growth hormone deficiency.
Yuen KC; Cook DM; Rumbaugh EE; Cook MB; Dunger DB
Horm Res; 2006; 65(1):6-13. PubMed ID: 16340214
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
20. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance.
Yuen K; Wareham N; Frystyk J; Hennings S; Mitchell J; Fryklund L; Dunger D
Eur J Endocrinol; 2004 Jul; 151(1):39-45. PubMed ID: 15248820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
